Respert was using Clue the other day. I think the
Post# of 148159
(Total Views: 1264)
Posted On: 02/26/2022 9:37:42 AM
Respert was using Clue the other day. I think there were some unmistakable clues back in the fall.
Brendan Rae rejoined CYDY in November. He did out-licensing (among other things) for Qilu. The same month when he rejoined our company, he made a comment on the NASH preclinical results that has resonance now:
Don't forget that just about the last thing that NP said was that partnership was looking very solid.
Dr. Kelly, meanwhile, has not only mentioned partnership quite a bit, he was at pains to mention that he thinks the future of the company is in oncology. Which could be translated to mean, We might sell the rights to partner with someone for NASH, but we're hanging to this baby for cancer.
I think that partnership might have been in the works since Sidley Austin was retained back in July. Someone might have wanted us to hang onto the rights to the drug, and not hand it over to the liquidating 13D crowd. After all, the Cytodyn that used Proinvestors videos for PRs was not exactly in the spendy league of companys who pay for the Sidley Austins of this world.
We suddenly splashed out on big time lawyers. We got Dr. Rae back. Kelly and Rae and Nader all spoke out about partnership. What's the obvious next move?
Brendan Rae rejoined CYDY in November. He did out-licensing (among other things) for Qilu. The same month when he rejoined our company, he made a comment on the NASH preclinical results that has resonance now:
Quote:
“The significant unmet medical need and the lack of approved treatment options for NASH has led to a healthy interest in licensing therapeutics, even those in the preclinical phase,” said Brendan Rae, Ph.D., J.D., CytoDyn Senior Vice President of Business Development. “Based on recent activity in the space, combined with leronlimab’s efficacy and human safety profile in the model, we expect there to be a significant interest from industry stakeholders in the development of leronlimab for the treatment of NASH.”
Don't forget that just about the last thing that NP said was that partnership was looking very solid.
Dr. Kelly, meanwhile, has not only mentioned partnership quite a bit, he was at pains to mention that he thinks the future of the company is in oncology. Which could be translated to mean, We might sell the rights to partner with someone for NASH, but we're hanging to this baby for cancer.
I think that partnership might have been in the works since Sidley Austin was retained back in July. Someone might have wanted us to hang onto the rights to the drug, and not hand it over to the liquidating 13D crowd. After all, the Cytodyn that used Proinvestors videos for PRs was not exactly in the spendy league of companys who pay for the Sidley Austins of this world.
We suddenly splashed out on big time lawyers. We got Dr. Rae back. Kelly and Rae and Nader all spoke out about partnership. What's the obvious next move?
(26)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼